Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study
2023-05-08 05:00
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
2023-05-08 05:00
First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide
2023-05-02 05:00
ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller
2023-05-01 08:58
Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
2023-04-27 06:50
Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter
2023-04-17 18:15
Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical
2023-04-17 06:38
Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate
2023-04-11 05:00
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
2023-03-16 20:28
FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy
2023-03-16 08:28
Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU
2023-03-14 05:11
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU
2023-03-09 04:51
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
2023-02-27 14:37
Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
2023-02-20 07:10
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
2023-02-15 04:51
Telix Reports Fourth Quarter 2022 Financial Results
2023-01-18 08:50
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
2023-01-09 06:37
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
2022-12-22 06:04
Telix Announces Executive Leadership Appointments
2022-12-05 06:39
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
2022-11-22 20:00
1
2
3
4
5
6